Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;33(4):527-541.
doi: 10.1111/pcmr.12861. Epub 2020 Jan 19.

Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions

Isabella C Glitza  1 , Keiran S M Smalley  2 , Priscilla K Brastianos  3 , Michael A Davies  1 , Ian McCutcheon  4 , James K C Liu  5 , Kamran A Ahmed  6 , John A Arrington  7 , Brittany R Evernden  5 , Inna Smalley  8 , Zeynep Eroglu  9 , Nikhil Khushalani  9 , Kim Margolin  10 , Harriet Kluger  11 , Michael B Atkins  12 , Hussein Tawbi  1 , Adrienne Boire  13 , Peter Forsyth  5
Affiliations
Review

Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions

Isabella C Glitza et al. Pigment Cell Melanoma Res. 2020 Jul.

Abstract

In February 2018, the Melanoma Research Foundation and the Moffitt Cancer Center hosted the Second Summit on Melanoma Central Nervous System Metastases in Tampa, Florida. The meeting included investigators from multiple academic centers and disciplines. A consensus summary of the progress and challenges in melanoma parenchymal brain metastases was published (Eroglu et al., Pigment Cell & Melanoma Research, 2019, 32, 458). Here, we will describe the current state of basic, translational, clinical research, and therapeutic management, for melanoma patients with leptomeningeal disease. We also outline key challenges and barriers to be overcome to make progress in this deadly disease.

Keywords: intrathecal therapy; leptomeningeal carcinomatosis; leptomeningeal disease; melanoma; neoplastic meningitis.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Schematic drawing of the blood–CSF and blood–brain barriers
FIGURE 2
FIGURE 2
Contrast enhanced axial imaging of the supratentorial brain (a,b) demonstrates curvilinear enhancement of the pial surface of the brain from leptomeningeal disease (LMD). Extensive pial enhancement involves the occipital and parietal cortex bilaterally (white arrows) as well as a focal nodular deposit involving the right frontal cortex (white curved arrow). Contrast enhanced axial imaging of the posterior fossa (c,d) demonstrates nodular enhancing LMD involving cranial nerves VII and VIII within the IAC and CPA (black block arrows), right cranial nerve V in lateral pontine cistern and Meckel’s cave (black arrows), as well as the folia of the cerebellum (white block arrows)
FIGURE 3
FIGURE 3
Contrast enhanced sagittal images of three different patients. First patient (a) does not have leptomeningeal disease (LMD) and demonstrates normal minimal enhancement involving the pial surface of the lower thoracic cord and conus (white arrows). Patient b has extensive smooth LMD involving the conus and cauda equine (white arrows). Patient c has more extensive and nodular LMD involving the lower thoracic cord and conus (black block arrows) and extensive focal leptomeningeal disease involving the sacral nerve roots (white block arrow)
See this image and copyright information in PMC

References

    1. Ahmed KA, Stallworth DG, Kim Y, Johnstone P, Harrison LB, Caudell JJ, … Gibney GT (2016). Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Annals of Oncology, 27(3), 434–441. 10.1093/annonc/mdv622 - DOI - PubMed
    1. Arasaratnam M, Hong A, Shivalingam B, Wheeler H, Guminksi AD, Long GV, & Menzies AM (2018). Leptomeningeal melanoma-A case series in the era of modern systemic therapy. Pigment Cell & Melanoma Research, 31(1), 120–124. 10.1111/pcmr.12652 - DOI - PubMed
    1. Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, … Margolin KA (2008). Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: A phase II Cytokine Working Group study. Cancer, 113(8), 2139–2145. 10.1002/cncr.23805 - DOI - PubMed
    1. Ballester LY, Glitza Oliva IC, Douse DY, Chen MM, Lan C, Haydu LE, … Davies MA (2018). Evaluating circulating tumor DNA from the cerebrospinal fluid of patients with melanoma and leptomeningeal disease. Journal of Neuropathology and Experimental Neurology, 77(7), 628–635. 10.1093/jnen/nly046 - DOI - PMC - PubMed
    1. Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, Junck L, … Soffietti R (2019). Liquid biopsy in central nervous system metastases: A RANO review and proposals for clinical applications. Neuro-Oncology, 21(5), 571–584. 10.1093/neuonc/noz012 - DOI - PMC - PubMed

MeSH terms

Substances